LIST OF TABLES

1) **Table 1.1** Telomere loss and linkage to disease or age related conditions.

2) **Table 1.2** Distribution of demographic variables for patients and controls.

3) **Table 1.3** State-wise distributions of lung cancer cases and controls from North India.

4) **Table 1.4** Distribution of cases and controls according to educational status.

5) **Table 1.5** Distribution of patients and controls on the basis of occupation.

6) **Table 2.1** Distribution of cases and controls by cyp1a1 genotypes.

7) **Table 2.2** Distribution of cases and controls by cyp2d6 and cyp2e1 genotypes.

8) **Table 2.3** Distribution of cases and controls by gstm1 and gstt1 genotypes.

9) **Table 2.3a** Odds ratio of lung cancer of cyp1a1, cyp2d6 and lung cancer.

10) **Table 2.3b** Odds ratio and 95%CI for lung cancer by, gstm1 and gstt1 genotypes.
11) **Table 3.1** Odds ratio of \textit{cyp1a1} (\textit{ile/val}) and \textit{cyp1a1} (\textit{msp1}) genotypes

12) **Table 3.1a** Odds ratio of SQCC of \textit{cyp1a1} (\textit{msp1}) and \textit{cyp1a1} (\textit{ile/val}) genotypes

13) **Table 3.1b** Odds ratio of SCLC of \textit{cyp1a1} (\textit{msp1}) and \textit{cyp1a1} (\textit{ile/val}) genotypes

14) **Table 4.1** Odds ratio of \textit{cyp2d6} and \textit{cyp1a1} (\textit{msp1}) genotypes with respect to lung cancer

15) **Table 4.2** Odds ratio of \textit{cyp2d6} and \textit{cyp1a1} (\textit{ile/val}) genotypes with respect to lung cancer

16) **Table 5.1** Odds ratio of \textit{gstm1} and \textit{cyp1a1} (\textit{msp1}) genotypes with respect to lung cancer

17) **Table 5.2** Odds ratio for the combined effect of \textit{gstm1} and \textit{cyp1a1} (\textit{ile/val}) genotype

18) **Table 6.1** Odds ratio for the combined effect of \textit{gstt1} and \textit{cyp1a1} \textit{msp1} genotype

19) **Table 6.2** Odds ratio for the combined effect of \textit{gstt1} and \textit{cyp1a1} \textit{ile/val} genotypes

20) **Table 7.1** Odds ratio for the combined effect of \textit{gstm1} and \textit{cyp2d6} genotypes

21) **Table 7.2** Odds ratio for the Combined effect of \textit{gstt1} and \textit{cyp2d6} genotypes

22) **Table 8.1** Odds ratio of lung cancer of \textit{gstm1} and \textit{gstt1} genotype
23) **Table 8.2**
Odds ratio of SQCC of gstm1 and gstt1 genotype combinations

24) **Table 8.3**
Odds ratio of SCLC of gstm1 and gstt1 genotype combinations

25) **Table 9.1**
Odds ratio of developing lung cancer with cyp1a1 ile/val, cyp1a1 msp1, gstm1, gstt1 genotypes stratified by smoking status

26) **Table 9.2**
Odds ratio of developing SQCC with cyp1a1 ile/val, cyp1a1 msp1, gstm1, and gstt1 genotypes stratified by smoking status

27) **Table 9.3**
Odds ratio of developing SCLC with cyp1a1 ile/val, cyp1a1 msp1, gstm1, and gstt1 genotypes stratified by smoking status

28) **Table 10.**
Relevant characteristics of lung cancer patients

29) **Table 10.1**
Patient and tumour characteristics of p53 mutations in patients with lung cancer

30) **Table 10.1.1**
Incidence of mutations in p53 in patients with lung cancer

31) **Table 10.2.1**
P53 gene mutations in different exons of both in cases with NSCLC and SCLC

32) **Table 10.2.2**
Distributions of mutations in different exons of p53 in patients with SCLC

33) **Table 10.2.3**
Distributions of p53 mutations in different exons of p53 with NSCLC
34) **Table 10.2.4** Distributions of multiple mutations in different exons in *p53* in patients with lung cancer.

35) **Table 10.3.1** Relationship of smoking index and *p53* mutations in patients with SQCC.

36) **Table 10.3.2** Relationship of smoking index and *p53* mutations in patients with SCLC.

37) **Table 10.4.1** Mutations in *p53* gene in lung cancer patients relation to smoking dose

38) **Table 10.4.2** Mutations in *p53* gene in patients with SQCC in relation to smoking dose

39) **Table 10.4.3** Mutations in *p53* gene in patients with SCLC in relation to smoking dose.

40) **Table 10.5.1** Odds ratio (95% CI) for mutations in *p53* gene in relation to *cyp1a1 (msp1)* genotype in lung cancer

41) **Table 10.5.2** Odds ratio (95% CI) for *p53* gene mutations in relation to *cyp1a1 (ile/val)* genotype in lung cancer

42) **Table 10.5.3** Odds ratio (95% CI) for *p53* gene mutations and combined *cyp1a1 (msp1/ile/val)* genotypes and lung cancer

43) **Table 10.6.1** Odds ratio (95% CI) for *p53* gene mutations and combined *cyp1a1 (msp1)* and *gstm1* genotypes and lung cancer
44) **Table 10.6.2**  Odds ratio (95% CI) for p53 gene mutations and combined *cyp1a1* (*ile/val*) and *gstm1* genotypes and lung cancer

45) **Table 10.7.1**  Odds ratio (95%CI) for p53 gene mutation in relation to *cyp2d6* genotypes and lung cancer

46) **Table 10.7.2**  Odds ratio (95% CI) for p53 gene mutations in relation to *cyp1a1* (*msp1*) and *cyp2d6* genotype in lung cancer

47) **Table 10.7.3**  Odds ratio (95% CI) for p53 gene mutations in relation to *cyp1a1* (*msp1*) and *cyp2d6* genotype in lung cancer

48) **Table 10.7.4**  Odds ratio (95% CI) for p53 gene mutations in relation to *gstt1* and *cyp2d6* genotype in lung cancer

49) **Table 10.8.1**  Odds ratio for the p53 gene mutations and *gstt1* genotypes in lung cancer

50) **Table 10.8.2.** Odds ratio (95%CI) for p53 gene mutation in relation to *gstt1* genotypes

51) **Table 11.1**  Telomerase activity in bronchial washings of lung cancer patients